Investigational drug · Phase 3
AU-011
Also called: Bel-sar
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
6
Any phase or sponsor naming "AU-011"
First trial start
2023
Dec 6, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AU-011", any sponsor or status.
Conditions studied
As listed on its trial records.
- Choroidal Melanoma
- Indeterminate Lesions
- Uveal Melanoma
- Ocular Melanoma
- Eye Cancer
- Primary Cancer
Approved drugs for the same conditions: Melanoma · Oncology · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "AU-011" as an intervention, largest first.
- A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal MelanomaPivotal-lookingActive, not recruiting
Aura BiosciencesIndustry
NCT06007690 · 108 participants · Start Dec 6, 2023 · Primary completion Nov 15, 2027
Drug: Bel-sar · For: Choroidal Melanoma; Indeterminate Lesions; Uveal Melanoma and 1 more
Sites: Los Angeles, California; Palo Alto, California; Sacramento, California · 53 sites in all
Aura BiosciencesIndustry
NCT03052127 · 57 participants · Start Feb 27, 2017 · Primary completion Jan 26, 2021
Drug: Light-activated AU-011 · For: Uveal Melanoma; Ocular Melanoma; Choroidal Melanoma
Sites: Tucson, Arizona; Los Angeles, California; Palo Alto, California · 13 sites in all
- A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder CancerActive, not recruiting
Aura BiosciencesIndustry
NCT05483868 · 55 participants (planned) · Start Sep 26, 2022 · Primary completion Mar 2027
Drug: AU-011 · For: Non-muscle-invasive Bladder Cancer; NMIBC; Non-Muscle Invasive Bladder Carcinoma and 3 more
Sites: Little Rock, Arkansas; Los Angeles, California; Santa Monica, California · 19 sites in all
Aura BiosciencesIndustry
NCT06643884 · 24 participants (planned) · Start Dec 16, 2024 · Primary completion Nov 30, 2026
Drug: AU-011 · For: Eye Cancer; Primary Cancer
Sites: Palo Alto, California; Miami, Florida; Boston, Massachusetts · 13 sites in all
Aura BiosciencesIndustry
NCT04417530 · 22 participants · Start Aug 5, 2020 · Primary completion Apr 22, 2024
Drug: AU-011 · For: Uveal Melanoma; Ocular Melanoma; Choroidal Melanoma
Sites: Tucson, Arizona; Los Angeles, California; Palo Alto, California · 22 sites in all
Aura BiosciencesIndustry
NCT05266430 · 2 participants · Start Apr 14, 2022 · Primary completion Feb 1, 2023
Drug: AU-011 · For: Choroidal Melanoma; Indeterminate Lesions
Sites: Royal Oak, Michigan; Portland, Oregon; Greenville, South Carolina · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- TGF-β-induced epithelial to mesenchymal transition drives proteoglycan binding specificity of HPV-based drug conjugates for cancer cells.
Fons NR, Kines RC, Azadi P, et al. · Front Oncol 2026
- Early Efficacy and Exploratory Biomarker Data of Bel-sar in Patients with Intermediate-risk and High-risk Non-muscle-invasive Bladder Cancer.
Linehan J, Agarwal PK, Penny X, et al. · Eur Urol Open Sci 2026
- Beyond the injection: delivery systems reshaping retinal disease management.
Rowe LW, Akotoye C, Harris A, et al. · Expert Opin Pharmacother 2025
- Targeting ocular malignancies using a novel light-activated virus-like drug conjugate.
Ma S, Huis In't Veld RV, Pinos EL, et al. · Adv Ophthalmol Pract Res 2025
- Suprachoroidal drug delivery: a versatile therapeutic platform.
Ciulla TA, Cunningham ET · Expert Opin Drug Deliv 2024
- Treatment of Conjunctival Melanoma Cell Lines With a Light-Activated Virus-Like Drug Conjugate Induces Immunogenic Cell Death.
Ma S, Huis In't Veld RV, de Los Pinos E, et al. · Invest Ophthalmol Vis Sci 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.